Is Roivant Sciences Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Roivant Sciences Ltd (ROIV) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Roivant Sciences Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Roivant Sciences Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Roivant Sciences Ltd?

Muslim investors may consider investing in Roivant Sciences Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Roivant Sciences Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Roivant Sciences Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Roivant Sciences Ltd updated?

The Shariah compliance status of Roivant Sciences Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Roivant Sciences Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Roivant Sciences Ltd?

You can check the latest Shariah compliance status of Roivant Sciences Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ROIV Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: February 09, 2026

Report Source: 2026 3rd Quarter Report

Roivant Sciences Ltd. Stock Analysis ROIV

United States Health Care Large Cap Report: Q3, 2026

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Key Statistics of Roivant Sciences Ltd (ROIV)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$28.73$29.62

Today's Open

$29.24

Volume

7.21M

P/E Ratio (TTM)

52 Week Range

$10.58$30.33

Market Cap

20.27B

Avg. Volume

5.05M

Dividend Yield

Financial Metrics & Statements of Roivant Sciences Ltd (ROIV)

FAQ's for Roivant Sciences Ltd (ROIV)

According to Musaffa’s Shariah screening methodology, Roivant Sciences Ltd (ROIV) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.